A prospective observational study of immune-related adverse events, treatment efficacy, and pre-existing autoantibodies in patients with small-cell lung cancer who was treated by immune checkpoint inhibitor
Not Applicable
- Conditions
- Patients with small cell lung cancer who was treated by chemotherapy plus immune checkpoint inhibitor as first line therapy
- Registration Number
- JPRN-UMIN000042962
- Lead Sponsor
- Kobe City Medical Center General Hospital Respiratory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who were determined as unsuitable by attending physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the incidence of immune-related adverse events
- Secondary Outcome Measures
Name Time Method The incidence of paraneoplastic syndrome Progression free survival Overall survival